In 2016, the U.S. Food and Drug Administration approved a clinical trial that marked a turning point in biomedical research: for the first time, aging itself was being studied as a treatable condition. The TAME trial, short for Targeting Aging with Metformin, was the brainchild of Dr. Nir Barzilai, a geneticist and professor at the Albert Einstein College of Medicine in New York City.
Rather than targeting individual diseases such as heart failure or Alzheimer’s, the trial uses metformin, a common diabetes medication, to test whether delaying the biological processes of aging can prevent multiple age-related illnesses at once. If successful, the TAME trial could reshape how regulators like the FDA view aging, moving it from an inevitable decline to a condition that is amenable to medical intervention.
Decades of Research into the Biology of Aging
Barzilai, an Israeli-American scientist, has spent decades focusing on the biology of aging as a target for biomedical research. He directs both the Institute for Aging Research and the Nathan Shock Center of Excellence in the Basic Biology of Aging at the Albert Einstein College of Medicine, both funded by the National Institutes of Health.
His approach differs from conventional medicine, which often fights diseases one by one, by instead addressing the underlying mechanisms of aging itself. This line of inquiry began in earnest with his flagship project, the Longevity Genes Project, launched in 1998. That study has enrolled over 600 Ashkenazi Jewish centenarians—individuals aged 95 and older—along with their children. By focusing on a genetically homogeneous population with extreme longevity, Barzilai’s team has identified specific genetic variants linked to longer life, including a variant of the CETP gene associated with lower cholesterol and a reduced risk of Alzheimer’s disease.
A key study published in 2013 in the Journal of the American Geriatrics Society found that centenarians have a 60% lower risk of cardiovascular disease compared to the general population. Over the course of his career, Barzilai has published more than 200 peer-reviewed papers on aging and longevity.
From Military Service to Leading a New Field
Born in Haifa, Israel, Barzilai served as a medical officer in the Israel Defense Forces, including during the 1976 Operation Entebbe. He earned his medical degree from the Technion – Israel Institute of Technology in 1985 before moving into aging research, eventually becoming a leading figure in the field of longevity studies.
His work has helped shift the emphasis of biomedical research from treating individual age-related diseases to addressing the underlying processes of aging. That shift has drawn attention from investors, policymakers, and fellow scientists. In 2021, Barzilai received the Irving S.
Wright Award from the American Federation for Aging Research (AFAR), an organization on whose board he has served since 2010. He is also a co-founder of the company CohBar, founded in 2008, which developed mitochondrial-derived peptides for aging.
The company ceased operations in 2023. Barzilai’s research has influenced both academic studies and commercial efforts to develop therapies that target aging directly.
What the Future Holds for Longevity Research
The TAME trial remains the most significant regulatory milestone in the field of aging research. If it yields positive results, it could redefine how the FDA and other global regulators view aging—not as an inevitable decline, but as a condition that can be intervened upon.
The data from the Longevity Genes Project and the TAME trial will help determine whether the field moves from a promising hypothesis to a proven intervention. By identifying genetic variants linked to extended lifespan and resistance to diseases like Alzheimer’s and cardiovascular disease, Barzilai’s findings continue to inform a new approach to medicine that might prevent or delay multiple age-associated conditions at once. For now, researchers and clinicians await the outcomes of these studies.
Consult your doctor for medical advice.
{“@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “Revolutionary Trial Aims to Treat Aging as a Medical Condition”, “description”: “NEW YORK, July 10 — In 2016, the U.S. Food and Drug Administration approved a clinical trial that marked a turning point in biomedical research:…”, “datePublished”: “2026-07-10T09:30:00+00:00”, “author”: {“@type”: “Person”, “name”: “James Roberto”}, “publisher”: {“@type”: “Organization”, “name”: “InfoPulse Today”, “url”: “https://newsfeed.infopulsetoday.com/”}}
